A Phase 2 Safety Study of Accelerated Elotuzumab Infusion, Over Less Than 1 H, in Combination With Lenalidomide and Dexamethasone, in Patients With Multiple Myeloma
American Journal of Hematology - United States
doi 10.1002/ajh.24687
Full Text
Open PDFAbstract
Available in full text
Categories
Date
March 22, 2017
Authors
Publisher
Wiley